Tourmaline Bio announces Dr. Paul Ridker's appointment to its Cardiovascular Scientific Advisory Board to guide inflammation treatment development.
Quiver AI Summary
Tourmaline Bio, Inc. has announced the appointment of Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board. Dr. Ridker, a prominent figure in cardiovascular research from Harvard Medical School, is renowned for his work on inflammation's role in atherosclerosis and its implications for cardiovascular disease treatment. His expertise will provide strategic guidance as Tourmaline progresses with its Phase 2 TRANQUILITY trial for pacibekitug, a monoclonal antibody targeting IL-6 to reduce inflammation in patients with cardiovascular diseases. Dr. Ridker's extensive contributions have influenced global clinical guidelines and supported the development of various anti-inflammatory therapies. Tourmaline is focused on developing transformative medicines for immune and inflammatory conditions, with pacibekitug currently being tested in cardiovascular disease and thyroid eye disease.
Potential Positives
- Dr. Paul M. Ridker, a leading figure in cardiovascular disease research, has joined Tourmaline’s Cardiovascular Scientific Advisory Board, enhancing the company's credibility and expertise in the field.
- Dr. Ridker's extensive background and his significant contributions to understanding inflammation in cardiovascular disease could provide valuable insights as Tourmaline advances its clinical program for pacibekitug.
- The press release highlights Tourmaline's commitment to developing innovative treatments for life-altering diseases, particularly with the ongoing Phase 2 TRANQUILITY trial for pacibekitug.
- Pacibekitug's unique properties as a long-acting, fully-human anti-IL-6 monoclonal antibody position it with best-in-class potential in the market for cardiovascular diseases.
Potential Negatives
- Potential risks related to the successful development and commercialization of their lead asset, pacibekitug, were highlighted, which may raise concerns among investors about the viability of the product.
- The press release emphasizes the uncertainties involved in clinical trials and regulatory approvals, which could suggest a lack of confidence in their upcoming trial results and market entry.
- The cautionary note regarding forward-looking statements points to significant risks that could lead to unfavorable outcomes for the company, impacting its financial stability and reputation.
FAQ
Who has joined Tourmaline Bio's Cardiovascular Scientific Advisory Board?
Dr. Paul M. Ridker has joined the board, known for his contributions to cardiovascular disease research.
What is the main focus of Tourmaline Bio?
Tourmaline Bio focuses on developing transformative medicines for patients with immune and inflammatory diseases.
What is pacibekitug?
Pacibekitug, also known as TOUR006, is an anti-IL-6 monoclonal antibody targeting cardiovascular diseases.
What are the indications for pacibekitug?
Pacibekitug is being developed for atherosclerotic cardiovascular disease and thyroid eye disease, with plans for more indications.
What significant research has Dr. Ridker conducted?
Dr. Ridker's research has focused on inflammation in atherosclerosis and the therapeutic benefits of targeting inflammation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TRML Insider Trading Activity
$TRML insiders have traded $TRML stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TRML stock by insiders over the last 6 months:
- SANDEEP CHIDAMBAR KULKARNI (CEO) has traded it 2 times. They made 2 purchases, buying 7,000 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TRML Hedge Fund Activity
We have seen 44 institutional investors add shares of $TRML stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 509,415 shares (+inf%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 338,437 shares (+inf%) to their portfolio in Q3 2024
- PICTET ASSET MANAGEMENT HOLDING SA added 247,140 shares (+inf%) to their portfolio in Q3 2024
- FMR LLC removed 221,665 shares (-93.6%) from their portfolio in Q3 2024
- BLUE OWL CAPITAL HOLDINGS LP removed 185,000 shares (-10.8%) from their portfolio in Q3 2024
- NORTHERN TRUST CORP added 143,769 shares (+303.2%) to their portfolio in Q3 2024
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 125,000 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, has joined Tourmaline’s Cardiovascular Scientific Advisory Board (CV SAB).
“We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of cardiovascular disease,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. “Dr. Ridker’s many contributions to cardiovascular disease research cannot be overstated. His work over decades has illuminated the critical role of inflammation in atherosclerosis, as well as the potential therapeutic benefit of directly addressing inflammation to reduce the risk of major adverse cardiovascular events. We are thrilled to have his invaluable strategic guidance as we await the results from our Phase 2 TRANQUILITY trial and prepare for the expected future development of pacibekitug to reduce inflammation in cardiovascular diseases.”
Over a 30-year period, Dr. Ridker has led a paradigm shift in the understanding of atherosclerotic cardiovascular disease (ASCVD), highlighting the critical importance of inflammation, and in doing so, has impacted international guidelines for the diagnosis, treatment, and prevention of ASCVD. He and his collaborators provided the first FDA-approved diagnostic test for vascular inflammation (high-sensitivity C-reactive protein, or hs-CRP); the first demonstration that statin therapy is both lipid-lowering and anti-inflammatory; and the first proof-of-principle for the inflammation hypothesis of atherothrombosis in humans, in addition to bringing into clinical practice worldwide the concept of “residual inflammatory risk.” As a direct result of his work, multiple novel anti-inflammatory agents targeting interrelated aspects of heart disease ranging from chronic ASCVD to acute myocardial ischemia to heart failure are under development worldwide.
Dr. Ridker, a Distinguished Scientist of the American Heart Association and an elected member of the National Academy of Medicine, is known for his leadership of over 15 major, multi-national, randomized clinical trials. He has received continuous funding from the National Institutes of Health and is the recipient of multiple honorary degrees and international awards.
“Dr. Ridker is a world-renowned pioneer in inflammation and cardiovascular disease whose ground-breaking work bridges population science, translational research, and clinical trials,” said Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline. “We are grateful to have his expert guidance as we advance development of pacibekitug for the treatment of patients with cardiovascular disease driven by residual inflammatory risk. Research he has led for decades, including prospective cohort studies of hs-CRP and the landmark CANTOS IL-1β inhibition trial, provides foundational evidence to support the therapeutic potential of IL-6 inhibition, which is currently being tested in multiple cardiovascular outcome trials.”
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline and pacibekitug, please visit
https://www.tourmalinebio.com
or follow us on
LinkedIn
or
X
.
About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Tourmaline’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of pacibekitug; the timing of initiation, progress and results of Tourmaline’s current and future clinical trials for pacibekitug, including reporting of data therefrom; the timing of Phase 3 clinical trial readiness; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline’s current or future product candidates; the risk that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
